Form 8-K - Groowe Newsroom

8-K — Viridian Therapeutics, Inc.\DE

Accession: 0001193125-26-130433

Filed: 2026-03-30

Period: 2026-03-30

CIK: 0001590750

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — d27955d8k.htm (Primary)

EX-99.1 (d27955dex991.htm)

EX-99.2 (d27955dex992.htm)

GRAPHIC (g27955ex99_2s10g1.jpg)

GRAPHIC (g27955ex99_2s11g1.jpg)

GRAPHIC (g27955ex99_2s12g1.jpg)

GRAPHIC (g27955ex99_2s13g1.jpg)

GRAPHIC (g27955ex99_2s14g1.jpg)

GRAPHIC (g27955ex99_2s15g1.jpg)

GRAPHIC (g27955ex99_2s16g1.jpg)

GRAPHIC (g27955ex99_2s17g1.jpg)

GRAPHIC (g27955ex99_2s18g1.jpg)

GRAPHIC (g27955ex99_2s19g1.jpg)

GRAPHIC (g27955ex99_2s1g1.jpg)

GRAPHIC (g27955ex99_2s20g1.jpg)

GRAPHIC (g27955ex99_2s21g1.jpg)

GRAPHIC (g27955ex99_2s22g1.jpg)

GRAPHIC (g27955ex99_2s23g1.jpg)

GRAPHIC (g27955ex99_2s24g1.jpg)

GRAPHIC (g27955ex99_2s25g1.jpg)

GRAPHIC (g27955ex99_2s26g1.jpg)

GRAPHIC (g27955ex99_2s27g1.jpg)

GRAPHIC (g27955ex99_2s28g1.jpg)

GRAPHIC (g27955ex99_2s29g1.jpg)

GRAPHIC (g27955ex99_2s2g1.jpg)

GRAPHIC (g27955ex99_2s30g1.jpg)

GRAPHIC (g27955ex99_2s31g1.jpg)

GRAPHIC (g27955ex99_2s32g1.jpg)

GRAPHIC (g27955ex99_2s33g1.jpg)

GRAPHIC (g27955ex99_2s34g1.jpg)

GRAPHIC (g27955ex99_2s35g1.jpg)

GRAPHIC (g27955ex99_2s36g1.jpg)

GRAPHIC (g27955ex99_2s37g1.jpg)

GRAPHIC (g27955ex99_2s38g1.jpg)

GRAPHIC (g27955ex99_2s39g1.jpg)

GRAPHIC (g27955ex99_2s3g1.jpg)

GRAPHIC (g27955ex99_2s40g1.jpg)

GRAPHIC (g27955ex99_2s41g1.jpg)

GRAPHIC (g27955ex99_2s42g1.jpg)

GRAPHIC (g27955ex99_2s43g1.jpg)

GRAPHIC (g27955ex99_2s44g1.jpg)

GRAPHIC (g27955ex99_2s45g1.jpg)

GRAPHIC (g27955ex99_2s46g1.jpg)

GRAPHIC (g27955ex99_2s47g1.jpg)

GRAPHIC (g27955ex99_2s48g1.jpg)

GRAPHIC (g27955ex99_2s49g1.jpg)

GRAPHIC (g27955ex99_2s4g1.jpg)

GRAPHIC (g27955ex99_2s50g1.jpg)

GRAPHIC (g27955ex99_2s51g1.jpg)

GRAPHIC (g27955ex99_2s52g1.jpg)

GRAPHIC (g27955ex99_2s53g1.jpg)

GRAPHIC (g27955ex99_2s54g1.jpg)

GRAPHIC (g27955ex99_2s55g1.jpg)

GRAPHIC (g27955ex99_2s56g1.jpg)

GRAPHIC (g27955ex99_2s57g1.jpg)

GRAPHIC (g27955ex99_2s58g1.jpg)

GRAPHIC (g27955ex99_2s59g1.jpg)

GRAPHIC (g27955ex99_2s5g1.jpg)

GRAPHIC (g27955ex99_2s60g1.jpg)

GRAPHIC (g27955ex99_2s61g1.jpg)

GRAPHIC (g27955ex99_2s62g1.jpg)

GRAPHIC (g27955ex99_2s6g1.jpg)

GRAPHIC (g27955ex99_2s7g1.jpg)

GRAPHIC (g27955ex99_2s8g1.jpg)

GRAPHIC (g27955ex99_2s9g1.jpg)

GRAPHIC (g27955g0327122033936.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: d27955d8k.htm · Sequence: 1

8-K

Viridian Therapeutics, Inc.\DE false 0001590750 0001590750 2026-03-30 2026-03-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 30, 2026

VIRIDIAN THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-36483

47-1187261

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

221 Crescent Street, Suite 103A

Waltham, MA

02453

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (617) 272-4600

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.01 par value

VRDN

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01

Regulation FD Disclosure.

On March 30, 2026, Viridian Therapeutics, Inc. (the “Company”) issued a press release announcing topline data from a phase 3 clinical trial of elegrobart, a subcutaneously delivered anti-insulin-like growth factor-1 receptor antibody, in patients with active thyroid eye disease, which the Company refers to as the REVEAL-1 trial. The Company also began using an updated corporate presentation, which includes the topline data.

A copy of the press release and the corporate presentation are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

The information in this Item 7.01 and in Exhibits 99.1 and 99.2 to this Current Report on Form 8-K is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

99.1

Press Release, dated March 30, 2026

99.2

Corporate Presentation, dated March 30, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Viridian Therapeutics, Inc.

Date: March 30, 2026

By:

/s/ Stephen Mahoney

Stephen Mahoney

President and Chief Executive Officer

EX-99.1

Filename: d27955dex991.htm · Sequence: 2

EX-99.1

Exhibit 99.1

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL-1 Clinical Trial in Active Thyroid Eye Disease

- REVEAL-1 met the primary endpoint of Q4W proptosis responder rate (PRR) with a highly statistically

significant treatment effect -

- Elegrobart Q4W and Q8W achieved clinically meaningful 54% and 63% PRR versus 18% placebo at week 24 -

- Complete resolution of diplopia in 51% of patients treated Q4W versus 16% placebo at week 24 -

- Elegrobart was generally well tolerated in both dose groups with low rates of hearing impairment -

- REVEAL-2, a phase 3 clinical trial evaluating elegrobart in patients with chronic TED, is on track for

topline readout in Q2 2026; BLA submission anticipated in Q1 2027 -

- Viridian ended Q4 2025 with $875 million in cash; the company

anticipates existing cash, potential near-term milestones from its 2025 royalty agreement, and anticipated commercial revenues from veligrotug and elegrobart if approved, to fund current business plans through profitability -

- Conference call and webcast to be held today, March 30th at 8:00 a.m. ET -

WALTHAM, Mass. – March 30, 2026—Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and

commercializing potentially best-in-class medicines for serious and rare diseases, today announced positive topline data from the elegrobart REVEAL-1 phase 3 clinical trial in patients with active thyroid eye disease (TED). Elegrobart is a subcutaneously delivered, half-life-extended monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R). REVEAL-1 evaluated two dosing regimens, every four weeks (Q4W) and every eight weeks (Q8W), compared with

placebo.

“We are excited to report these results from REVEAL-1, the largest pivotal clinical trial conducted in

active TED to date, which position elegrobart as potentially the first ever subcutaneous autoinjector treatment for TED,” said Steve Mahoney, President and Chief Executive Officer of Viridian Therapeutics.

“REVEAL-1 met its primary endpoint with high statistical significance. Elegrobart treatment drove robust proptosis responses in a treatment regimen comprised of as few as three subcutaneous doses.

Further, in the Q4W arm, we saw clinically meaningful diplopia responses and diplopia resolution. Currently, the only marketed treatment for TED requires eight intravenous infusions and, despite low market penetration, annualized in 2025 to

approximately $2B in revenues. We believe there is a significant opportunity with subcutaneous elegrobart in TED, including the potential to expand the market as an at-home and self-administered treatment

option, if approved.”

“Subcutaneous elegrobart showed rapid and clinically meaningful reductions in proptosis and diplopia in REVEAL-1 with a highly convenient, well-tolerated dosing profile,” said Prem Subramanian, MD, PhD, professor of ophthalmology at Colorado University Anschutz, and chief of neuro-ophthalmology at the Sue

Anschutz-Rodgers Eye Center. “Patients are seeking more treatment choices for TED, and there remains a clear need for a more conveniently administered therapy. I am very encouraged to see the data for elegrobart and believe it has the

potential to reach more TED patients than an intravenous therapy and to provide them with an attractive treatment option.”

Elegrobart REVEAL-1 Phase 3 Topline Results

REVEAL-1 assessed the efficacy and safety of subcutaneous Q4W or Q8W elegrobart versus placebo in patients with active TED. The

study enrolled 132 patients, randomized 1:1:1 to elegrobart Q4W (n=44), elegrobart Q8W (n=44), and placebo (n=44).

REVEAL-1 Efficacy

REVEAL-1 was highly statistically significant on its primary endpoint of Q4W proptosis responder rate and the key secondary endpoint of Q4W proptosis mean change from baseline, each at week 24 as measured by

exophthalmometry. REVEAL-1 also assessed elegrobart Q8W versus placebo and additional clinically relevant endpoints for both the Q4W and Q8W dosing arms. Detailed results are presented below:

Elegrobart

(n = 44 per

arm)

Placebo

(n = 44)

p-value

Primary Endpoint

Q4W

FDA: Proptosis responder rate (exophthalmometry)

54%

18%

p < 0.0001*

EMA: Overall responder rate (ORR)

51%

16%

p = 0.0001*

Key Secondary Endpoints

Q4W

Proptosis mean change from baseline (exophthalmometry)

-2.33 mm

-0.81 mm

p < 0.0001*

Clinical activity score (CAS) reduction to 0 or 1

57%

50%

p = 0.24

Diplopia responder rate

71%

32%

p = 0.0009

Diplopia complete resolution

51%

16%

p = 0.0013

Q8W

Proptosis responder rate (exophthalmometry)

63%

18%

p < 0.0001

EMA: Overall responder rate (ORR)

58%

16%

p < 0.0001

Proptosis mean change from baseline (exophthalmometry)

-2.50 mm

-0.81 mm

p < 0.0001

Clinical activity score (CAS) reduction to 0 or 1

69%

50%

p = 0.03

Diplopia responder rate

54%

32%

p = 0.05

Diplopia complete resolution

28%

16%

p = 0.14

Other Secondary Endpoints

Q4W

Proptosis responder rate (MRI)

50%

p < 0.0001

Proptosis mean change from baseline (MRI)

-2.04 mm

-0.22 mm

p < 0.0001

Q8W

Proptosis responder rate (MRI)

36%

p < 0.0001

Proptosis mean change from baseline (MRI)

-1.99 mm

-0.22 mm

p < 0.0001

Statistically significant. Key secondary endpoints below Q4W “CAS Reduction to 0 or 1” in the prespecified

testing hierarchy and other secondary endpoints are nominally significant if below the statistically significant threshold of 0.025.

REVEAL-1 Safety

Elegrobart was generally well-tolerated with a safety profile consisting of adverse events generally expected from the anti-IGF-1R class, the vast majority of which were mild. Rates of hearing impairment were low in both the Q4W and Q8W treatment arms (11.3% and 2.3% placebo-adjusted rates, respectively), and all reports were

of tinnitus, none of which were associated with reductions in hearing.

Elegrobart on Track with a BLA Submission anticipated in Q1 2027

•

Topline data from REVEAL-2 for patients with chronic TED, the second pivotal phase

3 clinical trial of elegrobart, remains on track to read out in Q2 2026.

•

Viridian anticipates submitting a Biologics License Application (BLA) to the U.S. FDA for elegrobart in Q1 2027.

Veligrotug on Track with a PDUFA Target Action Date of June 30, 2026

•

The veligrotug BLA is under Priority Review at the FDA with a Prescription Drug User Fee Act (PDUFA) target action date of

June 30, 2026. Veligrotug also received both Breakthrough Therapy Designation and Priority Review from the FDA in 2025.

•

Viridian is approaching full launch-readiness and is on track to support the PDUFA action date next quarter, with

experienced teams in place across field sales, field medical affairs, market access, and patient services .

•

Viridian anticipates the veligrotug commercial and medical affairs infrastructure will support a potential elegrobart

launch, if approved, with limited incremental investment, providing an infrastructure to support multiple treatment options for patients within the Viridian TED portfolio.

Conference call and webcast information

Viridian will host a conference call

today at 8:00 a.m. ET to discuss the REVEAL-1 topline data. The dial-in number for the conference call is (800) 715-9871 for

domestic participants and +1 (646) 307-1963 for international participants. The conference ID is 7373356.

A live webcast of

the conference call can be accessed through the “Events” page in the Investors section of the Viridian Therapeutics website. Following the live webcast, an archived version of the call will also be available on the website.

About Viridian Therapeutics

Viridian is a biopharmaceutical

company focused on discovering, developing, and commercializing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise

in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for validated drug targets and disease-driving mechanisms in autoimmune and rare diseases.

Viridian is advancing multiple late-stage, anti-insulin-like growth factor-1

receptor (IGF-1R) candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company conducted a pivotal program for veligrotug, including two global phase 3 clinical trials

(THRIVE and THRIVE-2), to evaluate its efficacy and safety in patients with active and chronic TED. Both THRIVE and THRIVE-2 reported positive topline data, meeting the

primary and all secondary endpoints of each study. Viridian is also advancing elegrobart as the potential first subcutaneous autoinjector for the treatment of TED, including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of elegrobart in patients with active and chronic TED.

In addition to its IGF-1R inhibitor portfolio, Viridian is developing an anti–thyroid-stimulating hormone receptor (TSHR) program designed as a potential therapy

for TED and Graves’ disease.

Viridian is also advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including

VRDN-006 and VRDN-008, which have the potential to be developed in multiple autoimmune diseases.

Viridian is based in Waltham, Massachusetts. For more information, please visit www.viridiantherapeutics.com. Follow Viridian on LinkedIn and X.

Forward Looking Statements

This press release contains

forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,”

“become,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,” “on track,” “plan,”

“potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or other similar terms or expressions that concern our expectations, plans and intentions.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions. Forward-looking statements include, without limitation, statements

regarding: preclinical development, clinical development, and anticipated commercialization of Viridian’s product candidates; anticipated data results and timing of their disclosure, including elegrobart topline data from the REVEAL-2 trial; Viridian’s expectations regarding the anticipated timing or likelihood of regulatory submissions and approvals, including the anticipated approval of the BLA for veligrotug and the anticipated

submission of a BLA for elegrobart; elegrobart’s potential to be the potential first subcutaneous autoinjector for the treatment of TED; that the veligrotug commercial infrastructure will support a potential elegrobart launch, if approved;

elegrobart’s potential to expand the market for products in TED, if approved; Viridian’s product candidates potentially being best-in-class; and that

Viridian’s cash, potential near-term milestones from its 2025 royalty agreement and anticipated commercial revenues, if veligrotug and elegrobart are approved, will be sufficient to fund its business plans through profitability.

New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or

implied) are made about the accuracy of any such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to: potential utility, efficacy, potency, safety,

clinical benefits, clinical response, and convenience of Viridian’s product

candidates; that results or data from completed or ongoing clinical trials may not be representative of the results of ongoing or future clinical trials; that the results of ongoing or future

clinical trials may not support submission for regulatory approvals; the timing, progress and plans for our ongoing or future research, preclinical, and clinical development programs; changes to trial protocols for ongoing or new clinical trials;

expectations and changes regarding the timing for regulatory filings; expectations and changes regarding the timing for enrollment and data; uncertainty and potential delays related to clinical drug development; the duration and impact of regulatory

delays in our clinical programs, including as a result of a prolonged government shutdown; the timing of and our ability to obtain and maintain regulatory approvals for our therapeutic candidates; manufacturing risks; competition from other

therapies or products; estimates of market size; other matters that could affect the sufficiency of existing cash, cash equivalents, and short-term investments to fund operations; our financial position; our future operating results and financial

performance; Viridian’s intellectual property position; that our product candidates may not be commercially successful, if approved; and other risks described from time to time in the “Risk Factors” section of our filings with the

Securities and Exchange Commission (SEC), including those described in our most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q, as applicable, and

supplemented from time to time by our Current Reports on Form 8-K. Any forward-looking statement speaks only as of the date on which it was made. Neither the company, nor its affiliates, advisors, or

representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be

relied upon as representing the company’s views as of any date subsequent to the date hereof.

Contacts

Investors

Greg Rossino

grossino@viridiantherapeutics.com

Media

Lisa Lopez

llopez@viridiantherapeutics.com

Source: Viridian Therapeutics, Inc.

EX-99.2

Filename: d27955dex992.htm · Sequence: 3

EX-99.2

Corporate Presentation March 2026

Exhibit 99.2

This presentation contains

forward-looking statements. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “become,” “continue,” “could,” “design,”

“estimate,” “expect,” “intend,” “may,” “might,” “on track,” “plan,” “potential,” “predict,” “project,” “should,”

“target,” “will,” or “would” or other similar terms or expressions that concern our expectations, plans and intentions. Forward-looking statements are neither historical facts nor assurances of future performance.

Instead, they are based on our current beliefs, expectations, and assumptions. Forward-looking statements include, without limitation, statements regarding: preclinical development, clinical development, and anticipated commercialization of

Viridian’s product candidates veligrotug, elegrobart, VRDN-006, and VRDN-008, including Viridian's view that the THRIVE and THRIVE-2 data provides support for ongoing elegrobart development; anticipated start dates of studies; anticipated data

results and timing of their disclosure, including the anticipated elegrobart topline data from the REVEAL-2 trial and VRDN-008 healthy volunteer clinical data; Viridian’s expectations regarding the anticipated timing or likelihood of

regulatory submissions and approvals, including the anticipated approval of the BLA for veligrotug, BLA submission for elegrobart, MAA submission for veligrotug, and IND submission for an anti-TSHR product candidate; the impact of Priority Review,

including the potential commercial launch of veligrotug in mid-2026, if approved; clinical trial designs, including the REVEAL-1 and REVEAL-2 global phase 3 clinical trials for elegrobart; the potential utility, efficacy, potency, safety, clinical

benefits, clinical response, convenience and number of indications of veligrotug, elegrobart, VRDN-006, VRDN-008 and Viridian’s anti-TSHR product candidate; the potential benefits of elegrobart; Viridian’s view of the strength of the

THRIVE durability data and veligrotug’s robust clinical profile; Viridian’s expectations regarding the potential commercialization of veligrotug and elegrobart, if approved, including plans to launch elegrobart with a low-volume

autoinjector; Viridian’s ability to receive milestone payments pursuant to the 2025 royalty agreement with DRI; the potential for veligrotug and elegrobart to transform the treatment for thyroid eye disease (TED); the potential for veligrotug

to be the IV treatment-of-choice for active and chronic TED; potential market sizes and market opportunities for Viridian’s product candidates, including Viridian’s belief that veligrotug is well-positioned to become a leading product in

the TED market and its FcRn portfolio has the potential to capture significant market share in autoimmune indications; Viridian’s product candidates potentially being best-in-class; Viridian’s anticipated pipeline expansion;

Viridian’s ability to expand to autoimmune disease beyond TED; and Viridian’s expectations regarding its ability to fund its current business through profitability. New risks and uncertainties may emerge from time to time, and it is not

possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Such forward-looking statements are subject to a number of material risks

and uncertainties including but not limited to: potential utility, efficacy, potency, safety, clinical benefits, clinical response, and convenience of Viridian’s product candidates; that results or data from completed or ongoing clinical

trials may not be representative of the results of ongoing or future clinical trials; that preliminary data may not be representative of final data; the timing, progress, and plans for our ongoing or future research, preclinical and clinical

development programs; changes to trial protocols for ongoing or new clinical trials; expectations and changes regarding the timing for regulatory filings; regulatory interactions; expectations and changes regarding the timing for enrollment and

data; uncertainty and potential delays related to clinical drug development; the duration and impact of regulatory delays in our clinical programs, including as a result of a prolonged government shutdown; the timing of and our ability to obtain and

maintain regulatory approvals for our therapeutic candidates; manufacturing risks; competition from other therapies or products; estimates of market size; other matters that could affect the sufficiency of existing cash, cash equivalents, and

short-term investments to fund operations; our future operating results and financial performance; Viridian’s intellectual property position; the timing of preclinical and clinical trial activities and reporting results from the same; and

those risks described from time to time under the caption “Risk Factors” in our filings with the Securities and Exchange Commission, including those described in our most recent Annual Report on Form 10-K or Quarterly Report on Form

10-Q, as applicable, and supplemented from time to time by our Current Reports on Form 8-K. The forward-looking statements in this presentation represent our views as of the date of this presentation. Neither we, nor our affiliates, advisors, or

relied upon as representing our views as of any date subsequent to the date of this presentation. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about

our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of

the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. Trademarks used herein are the property of their respective owners. Cautionary note regarding forward-looking statements

Viridian aspires to be a leading

autoimmune company… … starting with Best in TED In thyroid eye disease (TED), we aim to bring new treatment options to patients that address unmet needs and expand the number of treated patients

Continue to Advance and Expand

Pipeline * Planned; ** If approved. Ele = Elegrobart, FcRn = neonatal Fc receptor, IGF-1R = insulin-like growth factor-1 receptor, IND = investigational new drug application, POC = proof of concept, TED = thyroid eye disease, TSHR = thyroid

stimulating hormone receptor, Veli = Veligrotug. Viridian is building towards a leadership position in TED, enabling our expansion to other autoimmune diseases 2 Yrs 5 Yrs Commercial Company Revenue Funded Growth 2026 TSHR POC* FcRn POC* New

Pipeline INDs and POCs* Ele Topline* FcRn Expansion* TSHR IND* Ele Launch** Veli Launch** IGF-1R TED Autoimmune Thyroid

Primed for new entrants and growth Low

penetration with currently approved product No subcutaneous option available commercially Recent WW approvals is expanding the global market New-start market dynamic Limited competitive development landscape with high bar set by IGF-1R inhibitors

Current TED Market ~$2B1 Annualized TED market Source: 1Annualized TEPEZZA sales based on Amgen Q4 2025 Earnings, 2 Amgen Press Release “TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE

DISEASE,” 3 Amgen Press Release “AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY,” 4 Amgen Press Release “AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS,” 5 Amgen

Press Release “Amgen’s TEPEZZA®▼ (teprotumumab) granted marketing authorisation as the first targeted treatment specifically for adults with moderate-to-severe Thyroid Eye Disease (TED) in the United Kingdom,” 6 Viridian

THRIVE data on file, 7 Viridian THRIVE-2 data on file, 8 Planned product profile, including planned clinical dosing regimen, 9 Viridian REVEAL-1 data on file. BLA = Biologics License Application, IGF-1R = insulin-like growth factor-1 receptor, IND =

investigational new drug, IV = intravenous, TED = thyroid eye disease, TSHR = thyroid stimulating hormone receptor, SC = subcutaneous, WW = worldwide. Viridian is building a portfolio to address patient needs in TED with veligrotug, elegrobart, and

targeted pipeline expansion Veligrotug v Compelling profile with potential to be IV treatment of choice Potential to be first subcutaneous autoinjector in TED Elegrobart TSHR Inhibitor & Pipeline Transformative convenience of at-home

autoinjector every 4 or 8 weeks8 Potential to greatly expand TED market, if approved REVEAL-1 achieved its primary endpoint with high statistical significance9 REVEAL-2 topline data in chronic TED in Q2 2026 Generally well-tolerated9 Only remaining

autoinjector SC product in phase 3 development for TED Innovate for the future of TED PDUFA target: June 30, 2026 Robust and consistent clinical responses in active and chronic TED6,7 Rapid onset of treatment effect6,7 First statistically

significant demonstration of diplopia resolution and response in a global chronic TED phase 3 study7 Generally well-tolerated6,7 12-week treatment course TSHR product candidate designed to be best-in-class: half-life extension to support extended

dosing intervals in an autoinjector Potential in TED and Graves Anticipated IND Q4 2026 Evaluating novel treatments for the future of TED Elegrobart TSHR Inhibitor & Pipeline

BLA = biologics license application,

FcRn = neonatal Fc receptor, IND = investigational new drug application, TED = thyroid eye disease. Viridian has a proven track record of execution 1 $900 BLA submitted during the US government shutdown Secured access to up to ~$900M in capital in

2025, supporting funding of current business plans through profitability 8 2 8 phase 3 TED clinical trials conducted across veligrotug and elegrobart Advanced FcRn portfolio: 2 INDs submitted in two years 1200 2 >1200 TED patients enrolled in

Viridian clinical trials since January 2024 Granted 2 veligrotug regulatory designations in 2025: Priority Review, Breakthrough Therapy 6

DISCOVERY PRECLINICAL PHASE 1 PHASE 2

PHASE 3 Anticipated Milestones Thyroid Eye Disease Portfolio Veligrotug Anti-IGF-1R; Intravenous Elegrobart Anti-IGF-1R; Subcutaneous Anti-TSHR Subcutaneous FcRn-Targeting Autoimmune Portfolio VRDN-006 FcRn-targeting Fc fragment VRDN-008 Bispecific,

extended half-life FcRn inhibitor BLA = Biologics License Application, Fc = fragment crystallizable, FcRn = neonatal Fc receptor, HV = healthy volunteer, IGF-1R = insulin-like growth factor-1 receptor, IgG = immunoglobulin G, IND = Investigational

New Drug, PDUFA = Prescription Drug User Fee Act, TED = thyroid eye disease, TSHR = thyroid-stimulating hormone receptor, YE = year-end Strong and expanded TED portfolio and continued progress across FcRn inhibitors Communicate dev plan in 2026 HV

data 2H 2026 REVEAL-2 topline data Q2 2026 BLA submission Q1 2027 PDUFA target date June 30, 2026 IND Q4 2026 Potential in TED and Graves

Veligrotug Intravenous Elegrobart

Subcutaneous Anti-TSHR Subcutaneous FcRn inhibitor portfolio Subcutaneous Veligrotug PDUFA target date of June 30th and multiple additional anticipated value-creating catalysts portfolio-wide in 2026 2026 MAA Submission Jan 2026 PDUFA target date

June 30, 2026 REVEAL-1 Topline Q1 2026 REVEAL-2 Topline Q2 2026 IND Q4 2026 Strong balance sheet: $875M cash as of Dec 31, 2025; cash, anticipated near-term DRI milestone ($75M on veli U.S. approval), and future revenues, if both veligrotug and

elegrobart are approved, are expected to fund Viridian’s current business plans through profitability VRDN-008 HV Data: 2H 2026 ü ü BLA = Biologics License Application, FcRn = neonatal Fc receptor, HV = healthy volunteers, IND =

investigational new drug application, IV = intravenous, MAA = Marketing Authorisation Application, PDUFA = Prescription Drug User Fee Act, TED = thyroid eye disease, TSHR = thyroid-stimulating hormone receptor. 2027 BLA Submission Q1 2027

Veligrotug Intravenous

anti–IGF-1R

Sources: 1 George A et al. Front

Endocrinol (Lausanne). 2021;11:629925., 2 Smith TJ et al. NEJM. 2016;375(16):1552–1565., 3 Bahn RS. NEJM. 2010; 362(8): 726–738., 4 Bartley GB et al. Am J Ophthalmol 1996;121(3):284–290., 5 Viridian-sponsored market research,

includes active and chronic TED. TED patient images are from Bahn RS. NEJM. 2010; 362(8): 726–738. Copyright © (2010) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. IGF-1R = insulin-like

growth factor-1 receptor, TED = thyroid eye disease, TSHR = thyroid stimulating hormone receptor. TED is an autoimmune condition characterized by inflammation, growth, and damage to tissues around and behind the eyes Normal Eye Anatomy Bulging Eyes

Enlargement of extraocular muscles Optic Nerve Autoantibodies trigger IGF-1R/TSHR pathway1 Heterogeneous autoimmune disease with clinical signs and symptoms that can vary or modulate following onset, in some cases for the rest of a patient’s

life2,3 Main signs include proptosis (eye bulging), redness, swelling, diplopia (double vision), and lid retraction2,3 Severe cases can cause sight-threatening optic nerve compression4 An estimated 190K people in the US alone have moderate to severe

TED5 People living with TED experience proptosis, redness, swelling, diplopia, and lid retraction Thyroid Eye Disease (TED)

CHRONIC TED Key Inclusion Criteria

Proptosis of ≥3 mm Any CAS (0-7) Onset of TED symptoms >15 months Trial Design N = approx. 159 (actual enrollment: 188 patients) 15-week primary endpoint, 52-week total follow-up Double-masked, randomized, placebo-controlled ACTIVE TED Key

Inclusion Criteria Proptosis of ≥3 mm CAS ≥3 Onset of TED symptoms within 15 months Trial Design N = 90 (actual enrollment: 113 patients) 15-week primary endpoint, 52-week total follow-up Double-masked, randomized, placebo-controlled

Source: Viridian THRIVE and THRIVE-2 data on file. CAS = clinical activity score, FDA = Food and Drug Administration, mm = millimeter, PDUFA = Prescription Drug User Fee Act, TED = thyroid eye disease. Veligrotug granted Priority Review by the US

FDA, with PDUFA target date of June 30, 2026 Topline results reported December 2024 Met all primary & secondary endpoints Topline results reported September 2024 Met all primary & secondary endpoints Veligrotug met the primary and all

secondary endpoints with statistical significance in two phase 3 trials, THRIVE and THRIVE-2

Achieved the primary and all

secondary endpoints with high level of statistical significance (p < 0.0001) Source: Viridian THRIVE week 15 topline data on file (interim topline database lock) & week 52 data on file (final database lock). AE = adverse event, IGF-1R =

insulin-like growth factor-1 receptor, SAE = serious adverse event, TED = thyroid eye disease. THRIVE: Veligrotug showed robust and consistent clinical activity in active TED patients Rapid onset of treatment effect in as few as 3 weeks Generally

well-tolerated, with no treatment-related SAEs and low (5.5%) placebo-adjusted rate of hearing impairment AEs at week 15; consistent safety profile through week 52 Demonstrated strong durability of proptosis response: 70% of topline proptosis

responders maintained response at week 52 (Active TED) Detailed data can be found in appendix starting on slide 30

Source: Viridian THRIVE-2 week 15

topline data on file (interim topline database lock). AE = adverse event, IGF-1R = insulin-like growth factor-1 receptor, IV = intravenous, TED = thyroid eye disease. THRIVE-2: Demonstrated robust and consistent clinical activity in the largest and

broadest TED phase 3 study completed to date Achieved the primary and all secondary endpoints with statistical significance in largest IV IGF-1R antibody study in TED to date Rapid onset of treatment effect, with statistically significant proptosis

response in as few as 3 weeks First pivotal phase 3 study to demonstrate statistically significant diplopia response & resolution in chronic TED Generally well-tolerated, with low (9.6%) placebo-adjusted rate of hearing impairment AEs (Chronic

TED) Detailed data can be found in appendix starting on slide 40

Narrow and well-defined call point

supports small, efficient sales force Estimated ~2,000 core prescribers in the U.S.7 Tepro launched with field force of <100 sales reps8 Established market price and reimbursement pathway Current WAC price for tepro: ~$525K per complete treatment

course in the U.S.9 Established strong & deep KOL relationships Investigators have experience with veligrotug, one of the largest TED clinical program to date Sources: 1 Annualized teprotumumab sales based on Amgen Q4 2025 earnings, 2 Horizon 2Q

2020 and full-year 2020 earnings, 3 TEPEZZA® (teprotumumab-trbw) Patient Website, 4 Viridian-sponsored market research, includes active and chronic TED, 5 Amgen Q4 2025 earnings, 6 Viridian data on file, 7 Viridian internal claims analysis on

file, 8 FiercePharma, “Horizon bulks up sales force ahead of $750M inflammatory eye drug launch,” published: June 25, 2019, 9 Internal estimate, based on 80 kg patient. KOL = key opinion leader, TED = thyroid eye disease, Tepro =

teprotumumab, WAC = wholesale acquisition cost. Veligrotug’s robust clinical profile expected to drive rapid commercial adoption in TED, if approved Veligrotug is well-positioned to become the leading product in the new-start TED market ~$2B

single-product market in U.S.1 Tepro launch as first entrant: $166M net sales in first full quarter of launch (2Q 2020), and $820M in launch year2 Over 25k patients treated to date among estimated US prevalence of ~190K moderate to severe TED3,4,5

New-start market dynamic enables potential rapid uptake for new entrant Strong patient demand for new options >1200 TED patients enrolled in Viridian clinical trials since January 20246 Large & Growing Market Focused Footprint

Veligrotug and elegrobart are

investigational products that have not been approved by any regulatory authority; the safety and efficacy have not been established. Sources: 1 Viridian THRIVE data on file, 2 Viridian THRIVE-2 data on file, 3 Compared with current available

anti-IGF-1R treatment option. AE = adverse event, BLA = Biologic License Application, FDA = U.S. Food and Drug Administration, HCP = Health Care Professional, IV = intravenous, TED = thyroid eye disease. Approaching full launch-readiness in

preparation for June 30 PDUFA target action date under Priority Review Veligrotug is well positioned to become the IV treatment-of-choice for TED patients1,2 Generally Well Tolerated: Low rate of hearing impairment AEs Diplopia Resolution &

Response: Significant impact on diplopia in chronic TED Reduced Treatment Burden: ~70% shorter infusion time and shorter course of therapy3 Rapid Onset: Significant proptosis response demonstrated in as few as 3 weeks Launch preparations well

underway with experienced team in place Medical Affairs Full team engaging in scientific exchange Field Sales Wave one hires in market engaging with HCPs Patient Services Actively engaging offices and infusion centers in introductory conversations

Market Access Payer engagements ongoing with positive feedback on veli value Viridian go-to-market approach is grounded in comprehensive understand of the TED market Veligrotug received Breakthrough Therapy Designation (BTD) and Priority Review from

FDA

Elegrobart (VRDN-003) Subcutaneous

half-life extended anti–IGF-1R

Source: 1 Teprotumumab Prescribing

Information, 2 Planned product profile, including planned clinical dosing regimen. IGF-1R = insulin-like growth factor-1 receptor, IV = intravenous, Q4W = every 4 weeks, Q8W = every 8 weeks, SC = subcutaneous. Elegrobart has the potential to be the

first subcutaneous autoinjector in TED Potential to significantly reduce treatment burden for TED patients 6 SC Doses Self-administered every 4 weeks 1 loading dose + 5 Q4W 3 SC Doses Self-administered every 8 weeks + + 1 loading dose + 2 Q8W

Teprotumumab IV 1 8 INFUSIONS administered every 3 weeks Elegrobart Autoinjector 2 Phase 3 pivotal program is evaluating two dosing regimens: 60–90 min infusions = ~8–12 hours in an infusion chair + + + + + + + Elegrobart Benefits2

+ + + + + Half-life-extended, designed for infrequent administration every 4 weeks or every 8 weeks Self-administered autoinjector with ~10 second dosing time Potential to transform patient convenience with easy, at-home administration

CAS = clinical activity score, mm =

millimeter, TED = thyroid eye disease. REVEAL-1 and REVEAL-2 in active and chronic TED, respectively, form the foundation of elegrobart pivotal program Reported REVEAL-1 topline results in March, with REVEAL-2 expected in Q2 2026 CHRONIC TED Key

Inclusion Criteria Proptosis of ≥3 mm Any CAS (0–7) Onset of TED symptoms >15 months Trial Design N = 195 (actual enrollment: 204 patients) 24-week primary endpoint, 52-week total follow-up Double-masked, parallel-group,

placebo-controlled ACTIVE TED Key Inclusion Criteria Proptosis of ≥3 mm CAS ≥3 Onset of TED symptoms within 15 months Trial Design N = 117 (actual enrollment: 132 patients) 24-week primary endpoint, 52-week total follow-up Double-masked,

parallel-group, placebo-controlled Patients without response at 24 weeks may receive open-label elegrobart

Source: Viridian REVEAL-1 week 24

topline data on file (interim topline database lock). AE = adverse event, IGF-1R = insulin-like growth factor-1 receptor, PRR = proptosis responder rate, Q4W = every 4 weeks, Q8W = every 8 weeks, TED = thyroid eye disease. REVEAL-1 in active TED

patients met primary endpoint and elegrobart was generally well tolerated Achieved the primary endpoint with high statistical significance (p < 0.0001); 54% of Q4W patients achieved a proptosis response versus 18% placebo at week 24 Achieved

clinically meaningful outcomes on multiple secondary endpoints: 63% PRR in the Q8W arm versus 18% placebo, 51% diplopia complete resolution in the Q4W arm versus 16% placebo, all at week 24 Generally well tolerated in both dose groups, with low rate

of hearing impairment AEs through week 24 Elegrobart has the potential to be the first subcutaneous autoinjector in TED that allows patients to self-administer at home, with potentially as few as 3 doses (Active TED) Rapid onset of treatment effect

in as few as 4 weeks

1 600 mg loading dose given as two

300 mg injections; 2 Placebo injections administered at alternating study visits to maintain study masking across arms. D = day, mm = millimeter, Q4W = every 4 weeks, Q8W = every 8 weeks, TED = thyroid eye disease, W = week. REVEAL-1 is a phase 3

randomized, controlled, double-masked trial of elegrobart in active TED Follow-up through W52 Additional efficacy & safety follow-up at: Week 36 Week 52 Key Inclusion Criteria CAS ≥3 Onset of TED symptoms within 15 months Proptosis of

≥3 mm Treatment Phase (20 weeks treatment with primary endpoint at 24 weeks) Elegrobart Q4W1 D11 W4 W8 W12 W16 W20 Elegrobart Q8W1, 2 Placebo W24 Treatment Arms (1:1:1) Primary efficacy endpoint: Proptosis responder rate (PRR) in Q4W arm Key

secondary endpoints: Proptosis mean change from baseline Clinical Activity Score (CAS) reduction to 0 or 1 Diplopia responder rate Diplopia complete resolution Q8W endpoints Primary Endpoint Analysis Key: Elegrobart 300 mg Placebo

REVEAL-1 is the largest pivotal

clinical trial conducted in active TED to date Randomized Patients (n = 132) Elegrobart Q4W (n = 44) Placebo (n = 44) Elegrobart Q8W (n = 44) Completed Randomized Treatment (n = 35) Completed Randomized Treatment (n = 41) Completed Randomized

Treatment (n = 43) Discontinued 1 TEAE (Gr1 amylase / lipase elevation) 2 withdrawal of consent 2 lost to follow-up 2 failure to follow protocol 2 participant decision Discontinued 2 withdrawal of consent 1 lost to follow-up Discontinued 1 TEAE (Gr3

swollen tongue, Gr2 chest pain & Gr2 IRR) Source: Viridian REVEAL-1 week 24 topline data on file (interim topline database lock). Q4W = every 4 weeks, Q8W = every 8 weeks. Gr = grade, TEAE = treatment-emergent adverse event, IRR = infusion

related reaction.

7.8 Elegrobart Q4W (n = 44)

Elegrobart Q8W (n = 44) Placebo (n = 44) Participant Demographics Age in years, mean (SD) 52.6 (12.1) 48.1 (12.4) 48.5 (12.9) Female sex, n (%) 35 (80%) 34 (77%) 35 (80%) White race, n (%) 36 (82%) 36 (82%) 35 (80%) Disease Characteristics Months

since TED onset, mean (SD) 6.6 (4.4) 7.7 (4.3) 8.3 (5.2) Baseline proptosis by exophthalmometry (mm), mean (SD) 22.3 (2.6) 22.7 (3.3) 21.8 (2.5) Baseline CAS, mean (SD) 4.3 (1.0) 4.2 (1.0) 4.0 (0.9) Participants with diplopia, n (%) 28 (64%) 27

(61%) 31 (70%) Diplopia (Gorman Score), mean (SD)1 1.8 (0.8) 1.8 (0.8) 1.8 (0.7) Source: Viridian REVEAL-1 week 24 topline data on file (interim topline database lock). Note: all proptosis & CAS reported values and endpoints in the data analysis

are based on study eye (defined as eye with greater proptosis at baseline). 1 Of patients with diplopia at baseline. CAS = clinical activity score, mm = millimeter, SD = standard deviation, TED = thyroid eye disease. REVEAL-1 baseline

characteristics were well-balanced between arms

Elegrobart (n = 44 per arm) Placebo

(n = 44) p-value Primary Endpoint Q4W FDA: Proptosis responder rate (exophthalmometry)1 54% 18% p < 0.0001* EMA: Overall responder rate (ORR)2 51% 16% p = 0.0001* Key Secondary Endpoints Q4W Proptosis mean change from baseline

(exophthalmometry) -2.33 mm -0.81 mm p < 0.0001* Clinical activity score (CAS) reduction to 0 or 1 57% 50% p = 0.24 Diplopia responder rate3 71% 32% p = 0.0009 Diplopia complete resolution4 51% 16% p = 0.0013 Q8W Proptosis responder

rate (exophthalmometry)1 63% 18% p < 0.0001 EMA: Overall responder rate (ORR)2 58% 16% p < 0.0001 Proptosis mean change from baseline (exophthalmometry) -2.50 mm -0.81 mm p < 0.0001 Clinical activity score (CAS) reduction to 0 or

1 69% 50% p = 0.03 Diplopia responder rate3 54% 32% p = 0.05 Diplopia complete resolution4 28% 16% p = 0.14 Other Secondary Endpoints Q4W Proptosis responder rate1 (MRI) 50% 2% p < 0.0001 Proptosis mean change from baseline (MRI) -2.04 mm

-0.22 mm p < 0.0001 Q8W Proptosis responder rate1 (MRI) 36% 2% p < 0.0001 Proptosis mean change from baseline (MRI) -1.99 mm -0.22 mm p < 0.0001 Source: Viridian REVEAL-1 week 24 topline data on file (interim topline database lock). *

Statistically significant. Key secondary endpoints below Q4W “CAS Reduction to 0 or 1” in the prespecified testing hierarchy and other secondary endpoints are nominally significant if below the statistically significant threshold of

0.025. 1 Participants with ≥2 mm reduction in proptosis from baseline in study eye, without deterioration in fellow eye (≥2 mm increase), 2 Participants with both proptosis and CAS response; CAS response defined as ≥2-point

reduction in CAS from baseline in study eye, without deterioration in fellow eye (≥2-point increase), 3 Participants with reduction of ≥1 on Gorman Score at week 24, among patients with diplopia at baseline, 4 Participants with baseline

diplopia (Gorman Score >0) and a score of 0 at week 24. CAS = clinical activity score, mm = millimeter, MRI = magnetic resonance imaging, Q4W = every 4 weeks, Q8W = every 8 weeks. REVEAL-1 achieved high statistical significance on primary

endpoint at 24 weeks

Source: Viridian REVEAL-1 week 24

topline data on file (interim topline database lock). Primary endpoint was statistically significant. PRR at time points prior to week 24 were prespecified exploratory endpoints. Results at all time points and across both treatment arms prior to

week 24 were nominally significant (p < 0.025). PRR = proptosis responder rate, Q4W = every 4 weeks, Q8W = every 8 weeks. Rapid onset of treatment effect: proptosis response in patients receiving elegrobart was observed as early as week 4, after

just one dose Significant proptosis responder rate as early as 4 weeks after just one dose and across all time points in both arms Primary endpoint: p < 0.0001 Proptosis Responder Rate – Q4W Proptosis Responder Rate – Q8W Analysis

Visits Proptosis Responder Rate (%) 8% 30% Week 4 10% 37% Week 8 14% 45% Week 12 10% 43% Week 16 21% 54% Week 24 Elegrobart Q4W Week 20 62% 18% Analysis Visits Proptosis Responder Rate (%) 10% 43% 10% 63% 63% Elegrobart Q8W 18% Week 4 Week 8 Week 12

Week 16 Week 24 Week 20 62% 57% 31% 8% 14% 21%

Source: Viridian REVEAL-1 week 24

topline data on file (interim topline database lock). The key secondary endpoint of mean change from baseline at week 24 for Q4W arm was statistically significant. Proptosis mean change from baseline at time points prior to week 24 were prespecified

exploratory endpoints. Results at all time points and across both treatment arms prior to week 24 were nominally significant (p < 0.025). mm = millimeter, Q4W = every 4 weeks, Q8W = every 8 weeks. Significant proptosis mean change from baseline

at all time points across both treatment arms, including at week 4 Key secondary endpoint: p < 0.0001 Mean Change from Baseline – Q4W Mean Change from Baseline – Q8W Analysis Visits Proptosis Mean Reduction (mm) Elegrobart Q4W

Analysis Visits Proptosis Mean Reduction (mm) Elegrobart Q8W

Source: Viridian REVEAL-1 week 24

topline data on file (interim topline database lock). PRR and proptosis mean change from baseline at all time points prior to week 24 were prespecified exploratory endpoints. Results at all time points and across both treatment arms were nominally

significant (p < 0.025). MRI assessment was only conducted at baseline, week 12, and week 24. mm = millimeter, Q4W = every 4 weeks, Q8W = every 8 weeks. Proptosis Responder Rate (MRI) Proptosis Mean Change from Baseline (MRI) Proptosis endpoints

as measured by MRI were consistent with exophthalmometer, and significant at all time points Proptosis Mean Reduction (mm) Proptosis Responder Rate (%) Analysis Visits Elegrobart Q4W Analysis Visits Elegrobart Q8W Elegrobart Q4W Elegrobart Q8W

Source: Viridian REVEAL-1 week 24

topline data on file (interim topline database lock). Diplopia responder rate and diplopia complete resolution at time points prior to week 24 were prespecified exploratory endpoints. Q4W = every 4 weeks, Q8W = every 8 weeks. Diplopia responder rate

and complete resolution for patients receiving elegrobart Q4W improved throughout treatment period Diplopia Responder Rate – Q4W Diplopia Complete Resolution – Q4W Analysis Visits Elegrobart Q4W Analysis Visits Elegrobart Q4W Diplopia

Responder Rate (%) Diplopia Resolution Rate (%) Note: diplopia time course data not shown for Q8W treatment arm given week 24 endpoints did not meet nominal significance threshold

Source: Viridian REVEAL-1 week 24

topline data on file (interim topline database lock). 1 2 participants with 3 Gr3 SAEs: dehydration due to norovirus (unrelated), headache with left-ear tinnitus (related); 2 2 participants with 4 Gr3 SAEs: three abscesses (unrelated), pulmonary

embolism (unrelated); 3 Related TEAE discontinuation in placebo arm was due to Gr3 swollen tongue, Gr2 chest pain, & Gr2 IRR; 4 Unrelated TEAE discontinuation in Q4W arm was due to Gr1 amylase increase & Gr1 lipase increase. AE = adverse

event, MedDRA= medical dictionary for regulatory activities, SAE = serious adverse event, TEAE = treatment-emergent adverse event, Gr = grade, IRR = infusion related reaction. Elegrobart Q4W N=44 n (%) Elegrobart Q8W N=44 n (%) Placebo N=44 n (%)

Participants with any treatment-emergent adverse event (TEAE) 40 (91%) 31 (70%) 24 (55%) Participants with any serious AE (SAE) 2 (5%)1 2 (5%)2 0 Participants with any treatment-related TEAE 32 (73%) 22 (50%) 12 (27%) Participants with any

treatment-related SAE 1 (2%)1 0 0 Vast majority of TEAEs in both treatment arms were mild Only 2 treatment discontinuations due to TEAEs 1 in placebo arm (related TEAE)3 1 in elegrobart Q4W arm (unrelated TEAE)4 Elegrobart was generally well

tolerated through week 24

Source: Viridian REVEAL-1 week 24

topline data on file (interim topline database lock). 1 Includes multiple terms aggregated using standard sets of MedDRA terms; 2 All ISRs were Grade 1 except for one Grade 2 in Q8W arm (erythema), and majority of ISRs were erythema; 3 All hearing

impairment events in the treatment arms were tinnitus with no reductions in hearing. There was one hypoacusis event in placebo arm; 4 Reported as percentage of menstruating women. AE = adverse event, MedDRA = medical dictionary for regulatory

activities. AEs occurring at ≥10% frequency in any arm Elegrobart Q4W N=44 n (%) Elegrobart Q8W N=44 n (%) Placebo N=44 n (%) Muscle spasms 18 (41%) 16 (36%) 3 (7%) Injection site reactions (ISR)1,2 15 (34%) 9 (21%) 7 (16%) Headache 7 (16%) 3

(7%) 3 (7%) Ear discomfort 7 (16%) 3 (7%) 1 (2%) Alopecia 7 (16%) 3 (7%) 1 (2%) Diarrhea 6 (14%) 4 (9%) 2 (5%) Hearing impairment1,3 6 (14%) 2 (5%) 1 (2%) Hyperglycemia1 5 (11%) 5 (11%) 1 (2%) Injection related reactions (IRR)1 5 (11%) 2 (5%) 2 (5%)

Menstrual disorders1,4 5 / 17 (29%) 6 / 23 (26%) 1 / 20 (5%) AE categories for elegrobart in REVEAL-1 were consistent with those generally expected from the anti-IGF-1R class

Source: Viridian REVEAL-1 week 24

in as few as 4 weeks

REVEAL-2 in chronic TED, the second

pivotal phase 3 study for elegrobart, is on track for topline data readout in Q2 2026 CAS = clinical activity score, mm = millimeter, TED = thyroid eye disease. CHRONIC TED Patients without response at 24 weeks may receive open-label elegrobart

Trial Design N = 195 (actual enrollment: 204 patients) 24-week primary endpoint, 52-week total follow-up Double-masked, parallel-group, placebo-controlled Key Inclusion Criteria Proptosis of ≥3 mm Any CAS (0–7) Onset of TED symptoms

>15 months

1 Veligrotug and elegrobart are

investigational products that have not been approved by any regulatory authority. The safety and efficacy have not been established. Teprotumumab Prescribing Information, 2 Planned product profile, including planned clinical dosing regimen.

Veligrotug and elegrobart are investigational products that have not been approved by any regulatory authority. The safety and efficacy have not been established. IGF-1R = insulin-like growth factor-1 receptor, IV = intravenous, TED = thyroid eye

disease. Viridian has the potential to provide multiple differentiated treatment solutions for TED patients in one portfolio TED Past TED Present TED Future: Next-Gen Anti-IGF-1R Steroids/ Surgery Teprotumumab1 First approved targeted therapy for

TED Partial antagonist 8 IV infusions, administered every 3 weeks 60-90 min dosing Veligrotug2 Potential to become the IV treatment of choice in TED Full antagonist 5 IV infusions, administered every 3 weeks 30-45 min dosing Elegrobart2 Potential to

be the first subcutaneous autoinjector in TED Full antagonist Half-life-extended Self-admin autoinjector every 4 or 8 weeks ~10 sec dosing

FcRn Inhibitor Portfolio

Pathogenic autoantibodies cause

inflammation and damage to healthy tissues and cells, driving the pathology of autoimmune diseases1 Serum levels of pathogenic autoantibodies are maintained, in part, by FcRn-mediated recycling1 FcRn inhibition reduces pathogenic autoantibody

levels1, with demonstrated efficacy and safety in patients with gMG, CIDP, and ITP2 Source: 1 Pyzik M et al. Nat Rev Immunol. 2023;23:415–432, 2 Vyvgart Prescribing Information. CIDP = chronic inflammatory demyelinating

polyneuropathy, FcRn = neonatal Fc receptor, gMG = generalized myasthenia gravis, IgG = immunoglobulin G, ITP = primary immune thrombocytopenia. Pathogenic autoantibodies drive disease pathophysiology in a number of autoimmune diseases FcRn-Mediated

Recycling of IgGs, Including Pathogenic Autoantibodies1 1 2 3 4 IgGs, including pathogenic autoantibodies, enter the cell 1 IgGs and pathogenic autoantibodies bind to FcRns 2 Unbound antibodies are degraded by the lysosome 3 FcRn-bound IgGs,

including pathogenic autoantibodies, are recycled 4 IgG Degraded antibody FcRn Endosome Lysosome

Source: 1 Pyzik M et al. Nat

Rev Immunol. 2023;23:415–432. Fc = fragment crystallizable, FcRn = neonatal Fc receptor, IgG = immunoglobulin G. Viridian’s portfolio of FcRn inhibitors aims to reduce circulating levels of pathogenic autoantibodies by blocking FcRn

Fc fragment that blocks IgG from binding to FcRn Binds to albumin and FcRn for a more sustained reduction of pathogenic autoantibodies Fc fragment Fc fragment FcRn inhibitor and IgGs, including pathogenic autoantibodies, enter the cell 1 FcRn

inhibitor blocks IgGs from binding to FcRn 2 Unbound IgGs, including pathogenic autoantibodies, are degraded by the lysosome, reducing serum levels 3 The bound FcRn inhibitor and IgG are recycled and released 4 1 2 3 4 VRDN-006 VRDN-008 Albumin

binding domain Inhibition of FcRn Reduces IgGs, Including Pathogenic Autoantibodies1 FcRn Inhibitor IgG Degraded antibody FcRn Endosome Lysosome

Projected WW MG and CIDP FcRn

Market1 Source: 12024 revenues calculated from argenx (Vyvgart + Vyvgart Hytrulo), Zai Labs (Vyvgart), and UCB (Rystiggo) annual reported earnings; 2025 revenues calculated from preliminary argenx revenue disclosed in the January 12, 2026 press

release (Vyvgart and Vyvgart Hytrulo), 2025 Zai Labs Vyvgart revenue estimate based on Q3 2025 and Nine Months (through September 2025) revenue numbers in 10-Q filing, and UCB consensus estimates for Rystiggo as of February 25, 2026; 2030 estimates

based on Evaluate Pharma data for Vyvgart, Vyvgart Hytrulo, Rystiggo, Imaavy, batoclimab, and IMVT-1402, accessed February 2026. CIDP = chronic inflammatory demyelinating polyneuropathy, FcRn = neonatal Fc receptor, MG = myasthenia gravis, WW =

worldwide. FcRn inhibitors are a large market opportunity; market size of MG and CIDP alone are projected to be over $11B by 2030 ...with Potential in Additional Autoimmune Indications Sjogren’s Syndrome Lupus Nephritis Myositis Graves’

Disease $11.1B $2.5B $4.6B

Fc = fragment crystallizable, FcRn

= neonatal Fc receptor, FIH = first in human, IgG = immunoglobulin G, IND = Investigational New Drug, LDL = low-density lipoprotein, NHP = non-human primate, YE = year-end. Viridian’s FcRn portfolio has the potential to capture significant

market share in autoimmune indications VRDN-006 VRDN-008 v v IgG Suppression IgG reduction data consistent with the FcRn inhibitor class Deeper and more sustained reduction of IgG vs. efgartigimod in NHPs Dosing Targeting patient self-administration

in a convenient subcutaneous injection Targeting a less frequent, self-administered, subcutaneous injection Safety Spared albumin and LDL in healthy volunteers, generally well-tolerated Expect to maintain the Fc fragment safety profile Half-life

Extended Bispecific FcRn Inhibitor Highly Selective Fc Fragment and FcRn Inhibitor

Appendix 1) THRIVE in Active TED

Pivotal Data 2) THRIVE-2 in Chronic TED Pivotal Data 3) FcRn Non-Human Primate Data

THRIVE in Active TED Global phase 3

clinical trial pivotal data

D = day, mm = millimeter, TED =

thyroid eye disease, W = week. THRIVE is a phase 3 randomized, controlled, double-masked trial of veligrotug in active TED Treatment Phase (12-week treatment period with primary endpoint at 15 weeks) Veligrotug n = 75 D1 W3 W6 W9 W12 Placebo n = 38

Key: Veligrotug 10 mg/kg Placebo W15 Treatment Arms (2:1 randomization) Through W52 Additional efficacy & safety follow-up at: Week 24 Week 36 Week 52 Primary efficacy endpoint: Proptosis responder rate Key secondary endpoints: Proptosis mean

change from baseline Diplopia (double vision) Clinical Activity Score (CAS) Primary Endpoint Analysis Final THRIVE readout at Week 52 Key Inclusion Criteria CAS ≥3 Onset of TED symptoms within 15 months Proptosis of ≥3 mm

7.8 Veligrotug (n = 75) Placebo (n

= 38) Participant Demographics Age in years, mean (SD) 48.9 (12.4) 49.1 (12.5) Female sex, n (%) 56 (75%) 31 (82%) White race, n (%) 51 (68%) 19 (50%) Disease Characteristics Months since TED onset, mean (SD) 7.9 (3.7) 7.2 (3.8) Baseline proptosis

by exophthalmometry (mm), mean (SD) 23.2 (3.1) 23.2 (3.3) Baseline CAS, mean (SD) 4.5 (1.0) 4.8 (1.1) Participants with diplopia, n (%) 50 (67%) 26 (68%) Diplopia (Gorman Score), mean (SD)1 2.0 (0.8) 2.0 (0.7) Source: Viridian THRIVE week 15 topline

data on file (interim topline database lock). Note: all proptosis & CAS reported values and endpoints in the data analysis are based on study eye (defined as eye with greater proptosis at baseline). 1 Of patients with diplopia at baseline. CAS =

clinical activity score, mm = millimeter, SD = standard deviation, TED = thyroid eye disease. THRIVE baseline characteristics were well-balanced between active and placebo arms

Veligrotug (n=75) Placebo

(n=38) p-value Proptosis Primary Endpoint: Proptosis responder rate (exophthalmometry)1 70% 5% p < 0.0001 Proptosis mean change from baseline (exophthalmometry) -2.89 mm -0.48 mm p < 0.0001 Diplopia Diplopia complete

resolution2 54% 12% p < 0.0001 Diplopia responder rate3 63% 20% p < 0.0001 CAS Clinical activity score (CAS) 0 or 1 64% 18% p < 0.0001 CAS mean change from baseline -3.4 -1.7 p < 0.0001 Overall Response Overall responder rate (ORR)4 67%

5% p < 0.0001 Source: Viridian THRIVE week 15 topline data on file (interim topline database lock). 1 Percentage of participants with ≥2 mm reduction in proptosis from baseline in the study eye, without deterioration in the fellow eye

(≥2 mm increase), 2 Percentage of participants with baseline diplopia (Gorman Score >0) and a score of 0 at Week 15, 3 Percentage of participants achieving a reduction of at least 1 on the Gorman subjective diplopia scale at week 15, among

patients with diplopia at baseline, 4 Percentage of participants with ≥2 mm reduction in proptosis AND ≥2-point reduction in CAS from baseline in the study eye, without corresponding deterioration [≥2 mm/point increase] in

proptosis or CAS in the fellow eye. CAS = clinical activity score. THRIVE achieved high level of statistical significance across all primary and secondary endpoints at 15 weeks

Source: Viridian THRIVE week 15

topline data on file (interim topline database lock). Results at time points before week 15 are from post-hoc analyses and are for descriptive purposes only. mm = millimeter, PBO = placebo. Primary endpoint of proptosis responder rate met at 15

weeks: 70% for patients receiving veligrotug compared with 5% on PBO 53% of patients receiving veligrotug achieved a proptosis response at 3 weeks, after just 1 infusion of veligrotug Proptosis Responder Rate Proptosis Mean Change from Baseline

Proptosis Responder Rate (%) Proptosis Mean Reduction (mm) 53% 64% 64% 72% 70% Analysis Visits Veligrotug Analysis Visits Veligrotug

Source: Viridian THRIVE week 15

topline data on file (interim topline database lock). Results at time points before week 15 are from post-hoc analyses and are for descriptive purposes only. CAS = clinical activity score. Majority of patients receiving veligrotug had complete

resolution of diplopia and minimal disease activity (CAS) at week 15 Diplopia Complete Resolution CAS Score 0 or 1 Analysis Visits Diplopia Resolution Rate (%) Veligrotug 26% 32% 54% Diplopia Responder Rate at Week 15 63% 20% Diplopia Responder Rate

at Week 15 7% 25% 46% 24% 20% 64% 18% 64% Analysis Visits CAS 0 or 1 Rate (%) Veligrotug

Source: Viridian THRIVE week 15

topline data on file (interim topline database lock). CT = computed tomography, IGF-1R = insulin-like growth factor-1 receptor, mm = millimeter, MRI = magnetic resonance imaging. THRIVE demonstrated consistency between Hertel and MRI / CT and

validates both as reliable tools for measurements of proptosis Veligrotug (n=75) Placebo (n=38) Proptosis responder rate at week 15 70% 5% Proptosis mean change from baseline at week 15 -2.89 mm -0.48 mm Veligrotug (n=75) Placebo

(n=38) Proptosis responder rate at week 15 69% 9% Proptosis mean change from baseline at week 15 -2.91 mm -0.58 mm Hertel Exophthalmometry MRI / CT

Source: Viridian THRIVE week 15

topline data on file (interim topline database lock). 1 6 unrelated SAEs in 4 participants: cellulitis, appendicitis, dyspnoea, hyperthyroidism, aortic dissection (planned surgery for known Type B aortic dissection), depression (diagnosed prior to

1st dose); Includes multiple terms aggregated using standard sets of MedDRA terms. AE = adverse event, MedDRA= medical dictionary for regulatory activities, SAE = serious adverse event, TEAE = treatment-emergent adverse event. Veligrotug was

generally well-tolerated at week 15, with no treatment-related SAEs, and 96% of veligrotug-treated patients completed all doses Veligrotug N=75 n (%) Placebo N=38 n (%) Participants with any treatment-emergent adverse event (TEAE) 66 (88%) 24 (63%)

Participants with any serious AE (SAE) 4 (5%)1 0 Participants with any treatment-related TEAE 53 (71%) 9 (24%) Participants with any treatment-related SAE 0 0 Vast majority of TEAEs in both arms were mild Low treatment discontinuation rate 4% in

veligrotug arm No treatment-related SAEs

Source: Viridian THRIVE week 15

topline data on file (interim topline database lock). 1 Includes multiple terms aggregated using standard sets of MedDRA terms, 2 Reported as percentage of menstruating women. AE = adverse event, MedDRA = medical dictionary for regulatory

activities. Veligrotug was generally well-tolerated at week 15, with a 5.5% placebo-adjusted rate of hearing impairment AEs AEs occurring at ≥10% frequency in either arm Veligrotug N=75 n (%) Placebo N=38 n (%) Muscle spasms 32 (43%) 2 (5%)

Headache 16 (21%) 5 (13%) Infusion related reaction (IRR) 13 (17%) 1 (3%) Hearing impairment1 12 (16%) 4 (11%) Hyperglycemia1 11 (15%) 2 (5%) Fatigue1 10 (13%) 6 (16%) Nausea 10 (13%) 3 (8%) Ear discomfort 9 (12%) 1 (3%) Diarrhea 8 (11%) 1 (3%)

Alopecia 6 (8%) 4 (11%) Menstrual disorders1,2 8 / 34 (24%) 1 / 12 (8%)

Source: Viridian THRIVE week 52

data on file (final database lock). 1 Responders at week 15 who still had at least a 2-millimeter (mm) reduction in proptosis compared to baseline at week 52, without worsening in the fellow eye (≥2 mm increase), as measured by

exophthalmometry. Definition of durability is the same as that used for teprotumumab durability as reported in its U.S. Prescribing Information. No changes to veligrotug’s safety profile during the follow-up period Vast majority of adverse

events reported at topline resolved by Week 52 70% of proptosis responders in THRIVE maintained response at Week 52 in long-term follow up Proptosis Durability 70% (21/30 participants) of Week 15 proptosis responders maintained a proptosis response

at Week 521 Safety Resolution

THRIVE-2 in Chronic TED Global

phase 3 clinical trial pivotal data

D = day, mm = millimeter, TED =

thyroid eye disease, W = week. THRIVE-2 is a phase 3 randomized, controlled, double-masked trial of veligrotug in chronic TED Treatment Phase (12-week treatment period with primary endpoint at 15 weeks) Veligrotug n = 125 D1 W3 W6 W9 W12 Placebo n =

63 Key: Veligrotug 10 mg/kg Placebo W15 Treatment Arms (2:1 randomization) Through W52 Additional efficacy & safety follow-up at: Week 24 Week 36 Week 52 Primary efficacy endpoint: Proptosis responder rate Key secondary endpoints: Proptosis mean

change from baseline Diplopia (double vision) Clinical Activity Score (CAS) Primary Endpoint Analysis Final THRIVE-2 readout at Week 52 Key Inclusion Criteria Any CAS (0–7) Onset of TED symptoms >15 months Proptosis of ≥3

Source: Viridian THRIVE-2 week 15

topline data on file (interim topline database lock). Note: all proptosis & CAS reported values and endpoints in the data analysis are based on study eye (defined as eye with greater proptosis at baseline). 1 Of participants with diplopia at

baseline. CAS = clinical activity score, mm = millimeter, SD = standard deviation, TED = thyroid eye disease. THRIVE-2 baseline characteristics were well-balanced between active and placebo arms Veligrotug (n = 125) Placebo (n = 63) Participant

Demographics Age in years, mean (SD) 50.5 (13.5) 50.7 (12.0) Female sex, n (%) 95 (76%) 46 (73%) White race, n (%) 94 (75%) 48 (76%) Disease Characteristics Months since TED onset, mean (SD) 69.8 (78.9) 81.7 (83.7) Baseline proptosis by

exophthalmometry (mm), mean (SD) 24.3 (3.3) 23.8 (3.3) Baseline CAS, mean (SD) 2.7 (1.9) 2.5 (1.8) Baseline CAS 0 or 1, n (%) 44 (35%) 22 (35%) Baseline CAS ≥ 3, n (%) 71 (57%) 33 (52%) Participants with diplopia, n (%) 65 (52%) 37 (59%)

Diplopia (Gorman Score), mean (SD)1 2.0 (0.8) 2.1 (0.9)

Source: Viridian THRIVE-2 week 15

topline data on file (interim topline database lock). 1 Percentage of participants with ≥2 mm reduction in proptosis from baseline in the study eye, without deterioration in the fellow eye (≥2 mm increase), 2 Percentage of participants

achieving a reduction of at least 1 on the Gorman subjective diplopia scale, among patients with diplopia at baseline (n=102 participants), 3 Percentage of participants with baseline diplopia (Gorman Score >0; n=102 participants) and a score of 0

at the analysis timepoint, 4 Percentage of participants with ≥2 mm reduction in proptosis AND no worsening in CAS from baseline in the study eye, without corresponding deterioration (≥2 mm/point increase) in proptosis or CAS in the

fellow eye, 5 Of participants with CAS ≥3 at baseline (n=104 participants); CAS subpopulation analyses were prespecified, exploratory endpoints and statistical p values are for descriptive purposes only. CAS = clinical activity score. THRIVE-2

met all primary and secondary endpoints at 15 weeks Veligrotug (n=125) Placebo (n=63) p-value Proptosis Primary Endpoint: Proptosis responder rate (exophthalmometry)1 56% 8% p < 0.0001 Proptosis mean change from baseline

(exophthalmometry) -2.34 mm -0.46 mm p < 0.0001 Diplopia Diplopia responder rate2 56% 25% p = 0.0006 Diplopia complete resolution3 32% 14% p = 0.0152 Overall Response Overall responder rate (ORR)4 56% 7% p < 0.0001 CAS5 (prespecified

exploratory endpoints) Clinical activity score (CAS) reduction to 0 or 15 54% 24% p = 0.0060 CAS mean change from baseline5 -2.9 -1.3 p < 0.0001

Source: Viridian THRIVE-2 week 15

topline data on file (interim topline database lock). Results at time points before week 15 are from prespecified, exploratory endpoint analyses. Statistically significant proptosis responder rate at all time points, including at 3 weeks, after just

one infusion of veligrotug Rapid and statistically significant proptosis responder rate at 3 weeks, after just 1 infusion of veligrotug Proptosis Responder Rate Proptosis Mean Change from Baseline Proptosis Responder Rate (%) Proptosis Mean

Reduction (mm) Analysis Visits Veligrotug Analysis Visits Veligrotug 10% 25% 13% 40% 11% 50% 13% 54% 8% 56%

Source: Viridian THRIVE-2 week 15

topline data on file (interim topline database lock). Results at time points before week 15 are from prespecified, exploratory endpoint analyses. TED = thyroid eye disease. THRIVE-2 is the first phase 3 study in patients with chronic TED to

demonstrate statistically significant diplopia response & resolution Diplopia Responder Rate Diplopia Complete Resolution Diplopia Responder Rate (%) Analysis Visits Veligrotug Diplopia Resolution Rate (%) Analysis Visits Veligrotug 22% 29% 14%

47% 24% 52% 19% 55% 25% 56% 14% 18% 5% 31% 11% 36% 11% 33% 14% 32%

Source: Viridian THRIVE-2 week 15

topline data on file (interim topline database lock). Study eye is defined as eye with greater proptosis at baseline, as measured by corresponding measurement modality (i.e., Hertel study eye for Hertel endpoints, and MRI / CT study eye for MRI / CT

endpoints). CT = computed tomography, mm = millimeter, MRI = magnetic resonance imaging. THRIVE-2 demonstrated consistency between Hertel exophthalmometry and MRI / CT as measurements of proptosis THRIVE-2 demonstrated both exophthalmometry and MRI

/ CT are reliable tools for measurement of proptosis, building on data from THRIVE Hertel exophthalmometry MRI / CT Veligrotug (n=125) Placebo (n=63) Proptosis responder rate at week 15 56% 8% Proptosis mean change from baseline at week 15

-2.34 mm -0.46 mm Veligrotug (n=125) Placebo (n=63) Proptosis responder rate at week 15 48% 3% Proptosis mean change from baseline at week 15 -2.07 mm -0.36 mm

Source: Viridian THRIVE-2 week 15

topline data on file (interim topline database lock). 1 3 SAEs in 3 participants: Grade 3 vertigo (related), Grade 2 arthralgia (unrelated), Grade 2 metabolic encephalopathy (unrelated); 2 2 SAEs in 2 participants: Grade 3 urticaria (related), Grade

3 fatigue (unrelated). AE = adverse event, SAE = serious adverse event, TEAE = treatment-emergent adverse event. Veligrotug was generally well-tolerated, and 94% of veligrotug-treated patients completed their treatment course Veligrotug N=125 n (%)

Placebo N=63 n (%) Participants with any treatment-emergent adverse event (TEAE) 106 (85%) 43 (68%) Participants with any serious AE (SAE) 3 (2%)1 2 (3%)2 Participants with any treatment-related TEAE 79 (63%) 14 (22%) Participants with any

treatment-related SAE 1 (1%)1 1 (2%)2 Vast majority of TEAEs in both arms were mild Low treatment discontinuation rate 6% in veligrotug arm

Source: Viridian THRIVE-2 week 15

topline data on file (interim topline database lock). 1 Terms aggregated utilizing methodology used by FDA for approved products for treatment of thyroid eye disease, 2 Reported as percentage of menstruating women. AE = adverse event. Veligrotug was

generally well-tolerated, with a 9.6% placebo-adjusted rate of hearing impairment AEs AEs occurring at ≥10% frequency in either arm Veligrotug N=125 n (%) Placebo N=63 n (%) Muscle spasms 45 (36%) 4 (6%) Headache 18 (14%) 8 (13%) Hearing

impairment1 16 (13%) 2 (3%) Fatigue1 15 (12%) 5 (8%) Diarrhea 14 (11%) 6 (10%) Hyperglycaemia1 13 (10%) 3 (5%) Menstrual Disorders1,2 16 / 48 (33%) 2 / 20 (10%)

FcRn Non-Human Primate Data

Non-human primates (NHPs) were

dosed with IV bolus of 20 mg/kg VRDN-006, 20 mg/kg efgartigimod (internally generated benchmark), or buffer vehicle every 4 days for 4 doses. Source: Viridian data on file. IgG = Immunoglobulin G, IV = intravenous, NHP = non-human primate, PK =

pharmacokinetics, WT Fc = wild type neonatal fragment. VRDN-006 in vitro, multi-dose NHP PK and IgG reduction data compared to efgartigimod pH-Dependent Binding Internal Target Occupancy pH 7.4 pH 6 Multi-Dose NHP Pharmacokinetics Dose Dose v

Multi-Dose NHP Pharmacodynamics

VRDN-006 Spares Albumin VRDN-006

Spares LDL Non-human primates (NHPs) were dosed with IV bolus of 20 mg/kg VRDN-006, 20 mg/kg efgartigimod (internally generated benchmark), or buffer vehicle every 4 days for 4 doses. Source: Viridian data on file. CFB = change from baseline,

IV = intravenous, LDL = low-density lipoprotein, NHP = non-human primate. VRDN-006 spares albumin and LDL in multi-dose NHP study Dose Dose v

VRDN-008 Showed ~3x Longer

Half-life Head-to-Head vs. Efgartigimod in NHPs VRDN-008 Showed ~20% Deeper and More Sustained IgG Reduction Head-to-Head vs. Efgartigimod in NHPs v Non-human primates (NHPs) were given equimolar doses of 60 mg/kg VRDN-008, 48.5 mg/kg

efgartigimod (internally generated benchmark), or buffer vehicle - all via IV bolus. Source: Viridian data on file. BLQ = below limit of quantification, IgG = Immunoglobulin G, IV = intravenous, NHP = non-human primate. A single dose of

VRDN-008 demonstrated a longer half-life, deeper and more sustained reduction of IgG vs. efgartigimod Efgartigimod levels were BLQ at Days 35 and 42

VRDN-008 Spares Albumin VRDN-008

Spares LDL Non-human primates (NHPs) were given equimolar doses of 60 mg/kg VRDN-008, 48.5 mg/kg efgartigimod (internally generated benchmark), or buffer vehicle - all via IV bolus. Source: Viridian data on file. IV = intravenous, LDL =

low-density lipoprotein, NHPs = non-human primates. A single dose of VRDN-008 spares albumin and LDL in NHPs v

GRAPHIC

Filename: g27955ex99_2s10g1.jpg · Sequence: 7

Binary file (130163 bytes)

Download g27955ex99_2s10g1.jpg

GRAPHIC

Filename: g27955ex99_2s11g1.jpg · Sequence: 8

Binary file (124485 bytes)

Download g27955ex99_2s11g1.jpg

GRAPHIC

Filename: g27955ex99_2s12g1.jpg · Sequence: 9

Binary file (110733 bytes)

Download g27955ex99_2s12g1.jpg

GRAPHIC

Filename: g27955ex99_2s13g1.jpg · Sequence: 10

Binary file (113650 bytes)

Download g27955ex99_2s13g1.jpg

GRAPHIC

Filename: g27955ex99_2s14g1.jpg · Sequence: 11

Binary file (142603 bytes)

Download g27955ex99_2s14g1.jpg

GRAPHIC

Filename: g27955ex99_2s15g1.jpg · Sequence: 12

Binary file (142226 bytes)

Download g27955ex99_2s15g1.jpg

GRAPHIC

Filename: g27955ex99_2s16g1.jpg · Sequence: 13

Binary file (36276 bytes)

Download g27955ex99_2s16g1.jpg

GRAPHIC

Filename: g27955ex99_2s17g1.jpg · Sequence: 14

Binary file (112125 bytes)

Download g27955ex99_2s17g1.jpg

GRAPHIC

Filename: g27955ex99_2s18g1.jpg · Sequence: 15

Binary file (111679 bytes)

Download g27955ex99_2s18g1.jpg

GRAPHIC

Filename: g27955ex99_2s19g1.jpg · Sequence: 16

Binary file (130341 bytes)

Download g27955ex99_2s19g1.jpg

GRAPHIC

Filename: g27955ex99_2s1g1.jpg · Sequence: 17

Binary file (52352 bytes)

Download g27955ex99_2s1g1.jpg

GRAPHIC

Filename: g27955ex99_2s20g1.jpg · Sequence: 18

Binary file (105549 bytes)

Download g27955ex99_2s20g1.jpg

GRAPHIC

Filename: g27955ex99_2s21g1.jpg · Sequence: 19

Binary file (71236 bytes)

Download g27955ex99_2s21g1.jpg

GRAPHIC

Filename: g27955ex99_2s22g1.jpg · Sequence: 20

Binary file (95604 bytes)

Download g27955ex99_2s22g1.jpg

GRAPHIC

Filename: g27955ex99_2s23g1.jpg · Sequence: 21

Binary file (158645 bytes)

Download g27955ex99_2s23g1.jpg

GRAPHIC

Filename: g27955ex99_2s24g1.jpg · Sequence: 22

Binary file (116974 bytes)

Download g27955ex99_2s24g1.jpg

GRAPHIC

Filename: g27955ex99_2s25g1.jpg · Sequence: 23

Binary file (106296 bytes)

Download g27955ex99_2s25g1.jpg

GRAPHIC

Filename: g27955ex99_2s26g1.jpg · Sequence: 24

Binary file (97202 bytes)

Download g27955ex99_2s26g1.jpg

GRAPHIC

Filename: g27955ex99_2s27g1.jpg · Sequence: 25

Binary file (106816 bytes)

Download g27955ex99_2s27g1.jpg

GRAPHIC

Filename: g27955ex99_2s28g1.jpg · Sequence: 26

Binary file (95808 bytes)

Download g27955ex99_2s28g1.jpg

GRAPHIC

Filename: g27955ex99_2s29g1.jpg · Sequence: 27

Binary file (104184 bytes)

Download g27955ex99_2s29g1.jpg

GRAPHIC

Filename: g27955ex99_2s2g1.jpg · Sequence: 28

Binary file (273355 bytes)

Download g27955ex99_2s2g1.jpg

GRAPHIC

Filename: g27955ex99_2s30g1.jpg · Sequence: 29

Binary file (130486 bytes)

Download g27955ex99_2s30g1.jpg

GRAPHIC

Filename: g27955ex99_2s31g1.jpg · Sequence: 30

Binary file (76720 bytes)

Download g27955ex99_2s31g1.jpg

GRAPHIC

Filename: g27955ex99_2s32g1.jpg · Sequence: 31

Binary file (114234 bytes)

Download g27955ex99_2s32g1.jpg

GRAPHIC

Filename: g27955ex99_2s33g1.jpg · Sequence: 32

Binary file (31755 bytes)

Download g27955ex99_2s33g1.jpg

GRAPHIC

Filename: g27955ex99_2s34g1.jpg · Sequence: 33

Binary file (109552 bytes)

Download g27955ex99_2s34g1.jpg

GRAPHIC

Filename: g27955ex99_2s35g1.jpg · Sequence: 34

Binary file (106689 bytes)

Download g27955ex99_2s35g1.jpg

GRAPHIC

Filename: g27955ex99_2s36g1.jpg · Sequence: 35

Binary file (89378 bytes)

Download g27955ex99_2s36g1.jpg

GRAPHIC

Filename: g27955ex99_2s37g1.jpg · Sequence: 36

Binary file (105727 bytes)

Download g27955ex99_2s37g1.jpg

GRAPHIC

Filename: g27955ex99_2s38g1.jpg · Sequence: 37

Binary file (38447 bytes)

Download g27955ex99_2s38g1.jpg

GRAPHIC

Filename: g27955ex99_2s39g1.jpg · Sequence: 38

Binary file (34926 bytes)

Download g27955ex99_2s39g1.jpg

GRAPHIC

Filename: g27955ex99_2s3g1.jpg · Sequence: 39

Binary file (110397 bytes)

Download g27955ex99_2s3g1.jpg

GRAPHIC

Filename: g27955ex99_2s40g1.jpg · Sequence: 40

Binary file (91374 bytes)

Download g27955ex99_2s40g1.jpg

GRAPHIC

Filename: g27955ex99_2s41g1.jpg · Sequence: 41

Binary file (89636 bytes)

Download g27955ex99_2s41g1.jpg

GRAPHIC

Filename: g27955ex99_2s42g1.jpg · Sequence: 42

Binary file (105124 bytes)

Download g27955ex99_2s42g1.jpg

GRAPHIC

Filename: g27955ex99_2s43g1.jpg · Sequence: 43

Binary file (111077 bytes)

Download g27955ex99_2s43g1.jpg

GRAPHIC

Filename: g27955ex99_2s44g1.jpg · Sequence: 44

Binary file (95100 bytes)

Download g27955ex99_2s44g1.jpg

GRAPHIC

Filename: g27955ex99_2s45g1.jpg · Sequence: 45

Binary file (81720 bytes)

Download g27955ex99_2s45g1.jpg

GRAPHIC

Filename: g27955ex99_2s46g1.jpg · Sequence: 46

Binary file (95710 bytes)

Download g27955ex99_2s46g1.jpg

GRAPHIC

Filename: g27955ex99_2s47g1.jpg · Sequence: 47

Binary file (86720 bytes)

Download g27955ex99_2s47g1.jpg

GRAPHIC

Filename: g27955ex99_2s48g1.jpg · Sequence: 48

Binary file (80670 bytes)

Download g27955ex99_2s48g1.jpg

GRAPHIC

Filename: g27955ex99_2s49g1.jpg · Sequence: 49

Binary file (35805 bytes)

Download g27955ex99_2s49g1.jpg

GRAPHIC

Filename: g27955ex99_2s4g1.jpg · Sequence: 50

Binary file (90327 bytes)

Download g27955ex99_2s4g1.jpg

GRAPHIC

Filename: g27955ex99_2s50g1.jpg · Sequence: 51

Binary file (94169 bytes)

Download g27955ex99_2s50g1.jpg

GRAPHIC

Filename: g27955ex99_2s51g1.jpg · Sequence: 52

Binary file (98352 bytes)

Download g27955ex99_2s51g1.jpg

GRAPHIC

Filename: g27955ex99_2s52g1.jpg · Sequence: 53

Binary file (101007 bytes)

Download g27955ex99_2s52g1.jpg

GRAPHIC

Filename: g27955ex99_2s53g1.jpg · Sequence: 54

Binary file (109931 bytes)

Download g27955ex99_2s53g1.jpg

GRAPHIC

Filename: g27955ex99_2s54g1.jpg · Sequence: 55

Binary file (98238 bytes)

Download g27955ex99_2s54g1.jpg

GRAPHIC

Filename: g27955ex99_2s55g1.jpg · Sequence: 56

Binary file (102647 bytes)

Download g27955ex99_2s55g1.jpg

GRAPHIC

Filename: g27955ex99_2s56g1.jpg · Sequence: 57

Binary file (87883 bytes)

Download g27955ex99_2s56g1.jpg

GRAPHIC

Filename: g27955ex99_2s57g1.jpg · Sequence: 58

Binary file (74889 bytes)

Download g27955ex99_2s57g1.jpg

GRAPHIC

Filename: g27955ex99_2s58g1.jpg · Sequence: 59

Binary file (33457 bytes)

Download g27955ex99_2s58g1.jpg

GRAPHIC

Filename: g27955ex99_2s59g1.jpg · Sequence: 60

Binary file (110891 bytes)

Download g27955ex99_2s59g1.jpg

GRAPHIC

Filename: g27955ex99_2s5g1.jpg · Sequence: 61

Binary file (175799 bytes)

Download g27955ex99_2s5g1.jpg

GRAPHIC

Filename: g27955ex99_2s60g1.jpg · Sequence: 62

Binary file (87288 bytes)

Download g27955ex99_2s60g1.jpg

GRAPHIC

Filename: g27955ex99_2s61g1.jpg · Sequence: 63

Binary file (112024 bytes)

Download g27955ex99_2s61g1.jpg

GRAPHIC

Filename: g27955ex99_2s62g1.jpg · Sequence: 64

Binary file (88374 bytes)

Download g27955ex99_2s62g1.jpg

GRAPHIC

Filename: g27955ex99_2s6g1.jpg · Sequence: 65

Binary file (98017 bytes)

Download g27955ex99_2s6g1.jpg

GRAPHIC

Filename: g27955ex99_2s7g1.jpg · Sequence: 66

Binary file (96258 bytes)

Download g27955ex99_2s7g1.jpg

GRAPHIC

Filename: g27955ex99_2s8g1.jpg · Sequence: 67

Binary file (115393 bytes)

Download g27955ex99_2s8g1.jpg

GRAPHIC

Filename: g27955ex99_2s9g1.jpg · Sequence: 68

Binary file (31036 bytes)

Download g27955ex99_2s9g1.jpg

GRAPHIC

Filename: g27955g0327122033936.jpg · Sequence: 69

Binary file (3571 bytes)

Download g27955g0327122033936.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 71

v3.26.1

Document and Entity Information

Mar. 30, 2026

Cover [Abstract]

Entity Registrant Name

Viridian Therapeutics, Inc.\DE

Amendment Flag

false

Entity Central Index Key

0001590750

Document Type

8-K

Document Period End Date

Mar. 30, 2026

Entity Incorporation State Country Code

Entity File Number

001-36483

Entity Tax Identification Number

47-1187261

Entity Address, Address Line One

221 Crescent Street

Entity Address, Address Line Two

Suite 103A

Entity Address, City or Town

Waltham

Entity Address, State or Province

Entity Address, Postal Zip Code

02453

City Area Code

(617)

Local Phone Number

272-4600

Written Communications

false

Soliciting Material

false

Pre Commencement Tender Offer

false

Pre Commencement Issuer Tender Offer

false

Security 12b Title

Common Stock, $0.01 par value

Trading Symbol

VRDN

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration